

bioLytical Laboratories Inc. Announces Dr. Joshua Eades as New Chief Scientific Officer

RICHMOND, BRITISH COLUMBIA,
CANADA, July 19, 2021

/EINPresswire.com/ -- bioLytical
Laboratories Inc. ("bioLytical" or the
"Company"), a global leader in rapid
diagnostic tests for infectious diseases,
is pleased to announce the

appointment of Dr. Joshua Eades,
Ph.D., as the Company's new Chief

Scientific Officer, effective August 16, 2021. The change in leadership reflects bioLytical's
commitment to bringing innovative tests for infectious diseases to the world on our proven INSTI
rapid platform, leading the company's expansion into new markets.



“

Josh brings a wealth of
knowledge and experience
in the key areas of R&D,
innovative product lifecycle
management, and executive
leadership to strengthen
our commercialization and
global presence.”

Robert Mackie, CEO

“We are excited to welcome Josh to our leadership team,”
said Robert Mackie, CEO of bioLytical. “Josh brings a wealth
of knowledge and experience in the key areas of R&D,
innovative product lifecycle management, and executive
leadership to strengthen our commercialization and global
presence.”

As an accomplished and versatile chief officer,
entrepreneur, and scientific researcher, Dr. Eades brings a
wealth of experience and extensive knowledge in the
biotech and pharma development space. Most recently, Dr.
Eades spent seven years as Chief Science Officer at Tilray, a

global leader in medical cannabis research, cultivation, processing, and distribution. Here, he led
the company's research and product development teams to drive and implement innovative
commercial and clinical products and technologies. Prior to Tilray, Dr. Eades served as Senior
Technology Officer at the University of British Columbia, where he was active in transforming
and translating academic and hospital research to the private sector.

Dr. Eades has previously held research scientist roles in both the private and government sectors
and has been a co-founder and scientific advisor to various companies across different
industries. He has lectured graduate and undergraduate courses at the University of British

Columbia, Simon Fraser University, and the University of Victoria. Dr. Eades has been an invited speaker at numerous international conferences and seminars, has published papers in several high-impact journals, and is the inventor of multiple patent applications and issued patents. Dr. Joshua Eades holds a Ph.D. in Biology from the University of Victoria and a B.Sc. from the University of British Columbia.

About BioLytical

bioLytical Laboratories Inc. is a privately-owned Canadian company focused on the research, development and commercialization of rapid in vitro medical diagnostics using its proprietary INSTI® technology platform. bioLytical has won several local and industry awards, including B.C. Exporter of the Year in 2019. We have been named Lifesciences BC's Growth Stage Med Tech Company of the Year and have been featured on B.C.'s Fastest Growing Companies four years in a row, including the Globe and Mail's Fastest Growing Companies list in 2020. bioLytical moved to a significantly larger, state-of-the-art facility in Richmond, B.C., in 2020 to accommodate the extraordinary growth achieved through our team. Providing accurate results in one minute or less, the INSTI® range includes the INSTI HIV-1/HIV-2 Antibody Test, INSTI® Multiplex HIV Syphilis Ab Test, INSTI® HIV Self Test, INSTI® Covid-19 Antibody Test, and now the INSTI® HCV Antibody Test. bioLytical sells its products in Europe, North America, South America, Africa, and Asia.

By delivering accurate results in real-time, INSTI® generates meaningful outcomes for medical professionals, patients, and public health organizations worldwide and is a key partner in tackling some of the world's most severe healthcare challenges. Please visit www.insti.com and www.biolytical.com for more information.

Communications

bioLytical Laboratories Inc.

+1 866-674-6784

press@biolytical.com

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/546287700>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.